Integra LifeSciences (NASDAQ:IART) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

05 May 2026, 11:46 by Teresa Graham · The Cerbat Gem

Integra LifeSciences (NASDAQ:IART – Get Free Report) released its earnings results on Tuesday. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.41 by $0.13, FiscalAI reports. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same quarter in the previous year, the firm earned $0.41 earnings per share. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences updated its FY 2026 guidance to 2.400-2.500 EPS and its Q2 2026 guidance to 0.440-0.520 EPS.

Here are the key takeaways from Integra LifeSciences’ conference call:

Leadership change: Stuart Essig has resumed the CEO role (retaining Chairman) with a long-term commitment and the company added Michael McBreen as Chief Commercial Officer to sharpen commercial execution, culture, and customer focus.
Q1 beat and updated EPS guide: Q1 revenue was $392M and adjusted EPS $0.54 (above guidance); company maintained 2026 revenue guidance of $1.66B–$1.70B and raised full-year adjusted EPS to $2.40–$2.50, citing tariff benefits and operational improvements.
Tissue Reconstruction momentum and reimbursement positioning: Tissue Reconstruction grew ~6.4% organic (strong Integra Skin, DermaClose, PriMatrix), and management says ~90% of wound reconstruction revenue is inpatient (not impacted by new CMS outpatient skin substitute rules) with the portfolio priced to compete under the new reimbursement framework.
Quality, supply and product returns: The Compliance Master Plan remediation is progressing with improving supply reliability and Braintree production expected by end of June, but management says the 2026 guide does not rely on meaningful contribution from products still off-market.
Cash flow and leverage path: Q1 operating cash flow improved to $9.8M, the company expects ~+$150M in operating cash flow vs. 2025, reports net debt of $1.6B and a 4.1x leverage ratio with a plan to approach target leverage of 2.5x–3.5x by end of 2026.

Integra LifeSciences Price Performance

IART traded up $2.23 during trading hours on Tuesday, hitting $12.88. The company’s stock had a trading volume of 1,048,685 shares, compared to its average volume of 789,664. The business’s 50-day moving average price is $10.09 and its 200-day moving average price is $11.73. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $16.49. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -1.90 and a beta of 1.08. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently bought and sold shares of the business. Corient Private Wealth LLC bought a new stake in Integra LifeSciences in the fourth quarter worth $189,000. Virtu Financial LLC bought a new position in Integra LifeSciences during the fourth quarter valued at $124,000. Invesco Ltd. increased its position in Integra LifeSciences by 0.9% during the fourth quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after acquiring an additional 31,931 shares during the last quarter. State of Tennessee Department of Treasury increased its position in Integra LifeSciences by 7.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,745 shares of the life sciences company’s stock valued at $332,000 after acquiring an additional 1,964 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Integra LifeSciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 1,353,467 shares of the life sciences company’s stock valued at $16,810,000 after acquiring an additional 32,192 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

IART has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Friday, March 27th. Wall Street Zen downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Argus reissued a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Citigroup lowered their target price on shares of Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating on the stock in a report on Wednesday, March 11th. Finally, Wells Fargo & Company raised shares of Integra LifeSciences to a “hold” rating in a report on Wednesday, March 18th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $14.20.

View Our Latest Analysis on Integra LifeSciences

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

Positive Sentiment: Q1 beat on both EPS and revenue — Reported $0.54 EPS vs. $0.41 consensus and revenue $391.9M vs. ~$381.8M consensus; revenue up ~2.4% year‑over‑year, showing underlying demand resilience. GlobeNewswire: Q1 Results
Positive Sentiment: Raised FY‑2026 EPS guide — Company now targets $2.40–$2.50 vs. street ~2.35, implying confidence in full‑year profitability despite recent volatility. This upgrade helps justify upside in the shares. Zacks: Q1 & Guidance
Neutral Sentiment: Leadership transition announced — Stuart Essig named President & CEO (Michael McBreen appointed Chief Commercial Officer). Market reaction depends on investor confidence in the new leadership’s strategy and execution. GlobeNewswire: Leadership Transition
Negative Sentiment: Q2 guidance came in light — Q2 EPS guide of $0.44–$0.52 and revenue $410M–$425M are below consensus (EPS ~$0.53; revenue ~$425.3M), signaling near‑term pressure and creating a mixed read versus the raised full‑year view. That guidance softness likely capped further upside and introduces short‑term uncertainty. Zacks: Beat but Mixed Guidance

Integra LifeSciences Company Profile

(Get Free Report)

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.